Head and neck cancer and immunotherapy: current knowledge and perspective

Gauduchon, Thibault; Reverdy, Thibaut; Gau, Max; Karabajakian, Andy; Collet, Laetitia; Neidhardt, Ève-Marie; Fayette, Jérôme

doi:10.20517/2394-4722.2019.023

Cited by 3 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a higher infiltration of immune cells into the inflammatory and immunoreactive profiles classified as "hot tumors", making them more sensitive to immunotherapies. The important tumoral infiltration by the CD8 lymphocytes could further characterize this inflammatory type [7].…”

Section: The Immunosuppressive Landscape Of Hnsccmentioning

confidence: 99%

“…Interactions between PD-L1 and PD-1 can directly regulate the TME and have different functional significance in modulating the effects of T cells, DCs, MDSCs, and Tregs [32]. Reports show that the HPV + tumors respond better to anti-PD-1 [7]. HPV + tumors show enhanced immune infiltrates and more markers of activated T cells resulting in better efficacy of anti-PD-1 therapy.…”

Section: Immunotherapy With Antibodies To Immune Checkpointsmentioning

confidence: 99%

“…HPV + tumors show enhanced immune infiltrates and more markers of activated T cells resulting in better efficacy of anti-PD-1 therapy. A retrospective analysis of HNSCC patients who did not respond to platinum therapy was treated with pembrolizumab or nivolumab and significantly increased the OS for HPV + patients: 17 months vs. 4.5 months was observed [7]. A meta-analysis of PD-L1 expression was performed to predict the survival of HNSCC patients, no significant variance in OS between PD-L1 + and PD-L1-HNSCC patients were reported [178].…”

Section: Immunotherapy With Antibodies To Immune Checkpointsmentioning

confidence: 99%

See 2 more Smart Citations

Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is a relatively widespread cancer with high mortality rates. Many patients with locally advanced disease are treated with combinations of surgery, radiation, and chemotherapy, while others are considered incurable and develop recurrent/metastatic(R/M) disease. Despite these treatment modalities, the 5-year survival rate of HNSCC has remained at 50% due to limited treatment options in patients with recurrent disease. Immunotherapy has been shown to induce durable responses in R/M patients, but only a minority of patients currently respond. A major hurdle in tumor immunotherapy is identifying the non-responders and markers to predict resistance in patients who at first responded to the therapy. In HNSCC patients, the tumor microenvironment (TME) assumes a vital role to either diminish or augment immune responses. There is an urgent need for extensive studies to be undertaken to better understand how tumor cells escape immune surveillance and resist immune attack. In this review, the impact of TME on the efficiency of immunotherapy, addressing the factors that mediate therapy resistance are highlighted. The composition of the TME encompassing the immunosuppressive cells including myeloid-derived suppressor cell (MDSC), regulatory T cells (Treg), mesenchymal stem cell (MSC), cancer-associated fibroblast (CAF), and tumor-associated macrophages (TAMs) and intrinsic factors like hypoxia, reactive oxygen species (ROS),extracellular matrix (ECM), angiogenesis, and epithelial-mesenchymal transition (EMT), how this debilitates immunosurveillance, and also discuss existing and potential strategies aimed at targeting these cellular and molecular TME components are reviewed. Understanding the interactions between the TME and immunotherapy is not only important in dissevering the mechanisms of action of immunosuppression but also offers scope for developing newer strategies to improve the competence of current immunotherapies.

show abstract

Section: The Immunosuppressive Landscape Of Hnsccmentioning

confidence: 99%

Section: Immunotherapy With Antibodies To Immune Checkpointsmentioning

confidence: 99%

Section: Immunotherapy With Antibodies To Immune Checkpointsmentioning

confidence: 99%

See 1 more Smart Citation

Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, increased PD-L1 protein expression allows cancer cells to evade the body's immune response. Instead, targeting the PD-1/PD-L1/2 pathway allows for the activation of anti-tumour immunity and better cancer treatment [2,14,20,23,28].…”

mentioning

confidence: 99%

Pembrolizumab as an immunotherapy drug in the treatment of a patient with recurrent (unresectable) cancer of the lower lip

Markulan

Makarevych

2022

ЗХ

View full text Add to dashboard Cite

Advances in immunotherapy have changed approaches to the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The US Food and Drug Administration (the FDA) has approved both pembrolizumab monotherapy for first‑line treatment of the tumours expressing the programmed cell death receptor‑1 (PD‑L1; combined positive score of ≥ 1) in patients with R/M HNSCC and pembrolizumab administration in combination with platinum and fluorouracil regardless of the level of PD‑L1 expression. Pembrolizumab is a humanized monoclonal antibody class drug that activates the anti‑tumour immune response. Objective — to present treatment outcomes for recurrent (unresectable) cancer of the lower lip that was treated using a pembrolizumab monotherapy regimen. Patient H., born in 1968, received a 20‑month combined therapy for cancer of the lower lip. He had radical surgical removal of the primary tumour and two surgical resections of metastases, as well as courses of both remote gamma‑therapy and polychemotherapy. Nevertheless, the disease progressed from T2N0M0 to T4N1M0. In the area of the chin and right cheek, the patient developed a defect of the skin and subcutaneous tissue measuring 18 ´ 10 cm with purulent‑necrotic margins and an external fistula of the oral cavity. He was also bothered by unbearable pain in the area of the tumour and an unpleasant odour from the mouth and from the tumour. The patient was prescribed immunotherapy with pembrolizumab since an immunohistochemical examination revealed an RD‑L1‑positive tumour. One year after the start of immunotherapy, which included 17 courses of cancer treatment, the wound healed and the patient’s quality of life significantly improved. No adverse reactions were observed during immunotherapy. Computed tomography revealed a 25 x 15 mm nodule at the level of the lower jaw on the right and a lymph node of about 10 mm in diameter in the area of the lower parts of the right parotid salivary gland. Distant metastases were not detected. Currently, immunotherapy is ongoing. The issue of surgical removal of pathological formations is under consideration. This case demonstrates the positive outcomes of a pembrolizumab monotherapy regimen in a patient with R/M HNSCC.

show abstract

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

Poulose¹,

Kainickal²

2022

WJCO

View full text Add to dashboard Cite

Head and neck cancer and immunotherapy: current knowledge and perspective

Cited by 3 publications

References 26 publications

Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy

Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy

Pembrolizumab as an immunotherapy drug in the treatment of a patient with recurrent (unresectable) cancer of the lower lip

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

Contact Info

Product

Resources

About